AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05396820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pain
Description: Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
Study NCT04307433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
Study NCT04307433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
Study NCT04307433 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Storytelling narrative videos on tablets
Description: The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
Study NCT05240430 — intervention group
Intervention type: DRUG
Intervention: Mesenchymal Stem Cell Antigen-1, Human
Description: Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
Study NCT06432075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Reactive T Cells(NRTs)
Description: Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
Study NCT05313386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: BXCL501 is given in a film form
Study NCT05313386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Placebo is given in a film form
Study NCT05392023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Exercises and Scapular Stabilization exercise program
Description: Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
Study NCT05392023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation Exercises of cervico- scapular region
Description: Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
Study NCT05709028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~* Children ≥ 6 months to \<1 year old will be administered 30ml (=1g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥12 and \<18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose.
Study NCT05709028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care antibiotics
Description: Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
Study NCT04903353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of Risperidone and Aripiprazole
Description: Comparing two FDA approved medications for treatment of irritability in autism
Study NCT05311436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children
Description: Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation.~Adolescent girls: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for 6 months. Iron and folic acid (200 mg ferrous fumarate and 400 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month.~Children \<2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety.~Intensive WASH counselling: Intensive WASH counseling will be provided to separate group of child participants twice a month for 6 months.~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 2 months.
Study NCT04843722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
Study NCT04073433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 120 mg midomafetamine HCl
Study NCT04073433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy conducted during MDMA-assisted therapy session
Study NCT05717062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib intravenous form
Description: This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
Study NCT05717062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib-methyl- oral form
Description: Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
Study NCT05717062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intravenous form
Description: The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
Study NCT05717062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - oral form
Description: Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
Study NCT05345002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
Study NCT05345002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
Study NCT06641128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX SC or IM
Description: IM or SC Methotrexate
Study NCT06641128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX SC or IM
Description: IM or SC Methotrexate
Study NCT06641128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg tab
Description: Empa tablets 25 mg once daily for 3 months.
Study NCT05163275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video recording and EMG
Description: The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total
Study NCT05933174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prompt-sheet
Description: Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
Study NCT05933174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual education
Description: Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
Study NCT05944783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 100 MG
Description: single dose of 100 mg Dasatinib tablets
Study NCT06660381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
Study NCT06665191 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational study for prevalence of dental wear and its association with quality of life
Description: not applicable as it is an observational study testing the prevalence of dental wear in patients attending Cairo University
Study NCT06665165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0114
Description: Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
Study NCT06665165 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06665958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol extract
Description: Single dose
Study NCT06140355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
Study NCT06140355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily 2 min pain management survey
Description: Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
Study NCT06666556 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bowel preparation before colonoscopy
Description: In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrafractionated RT and CGA Guided systemic treatment.
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
Study NCT06665087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrafractionated Radiotherapy
Description: 1Fx every 3 or 4weeks
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Fluorouracil)
Description: 5-Fluorouracil or capecitabine
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Fluorouracil)
Description: 5-Fluorouracil or capecitabine
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Raltitrexed)
Description: Raltitrexed
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Raltitrexed)
Description: Raltitrexed
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Oxaliplatin)
Description: Oxaliplatin
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Oxaliplatin)
Description: Oxaliplatin
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CPT-11)
Description: Irinotecan
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (CPT-11)
Description: Irinotecan
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy (anti-VEGF)
Description: anti-VEGF antibody
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Targeted Therapy (anti-VEGF)
Description: anti-VEGF antibody
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Therapy (anti-EGFR)
Description: anti-EGFR antibody
Study NCT06665087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Targeted Therapy (anti-EGFR)
Description: anti-EGFR antibody
Study NCT06667219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A relevant physical fitness training program intervention
Description: 54children who participated in after-school sports activities in Guangzhou Kindergarten (Guangzhou, China) were randomly selected as the experimental group.~Intervention group Length:12 weeks, 40 minutes, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program , as follows: Week 1 / 4 first: Run quickly;Durian ball;Throw;Fast jogging (200 m) Week 1 / 4 second: Dodge run,Raise your legs high and go over the small hurdles; Durian ball (standing on one foot);standing long jump Week 2 / 5 first: Bow step transformation jump;Throw;Turn back 10 meters Week 2 / 5 second: Hop ;Stand on one foot with your eyes open Week 3 / 6 first:Skip over the small hurdles;Durian ball (standing on one foot);Throw; Fast jogging (200 m) Week 3 / 6 second:Jump on your feet and dodge running;Durian ball (squat);Jump support Weeks 7-12,Repeat the above content. FMS index was tested before the experiment, and once after the intervention.
Study NCT06667219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group,Physical exercise using kindergarten standards
Description: 54 children who did not participate in after-school sports activities were selected as the control group.~control group Duration: 12 weeks. Content: Physical exercise using kindergarten standards. FMS index was tested the same to intervention group before the test and FMS index was measured once again after 12 weeks.
Study NCT04731155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor （Alirocumab）plus standard medications
Description: PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
Study NCT04731155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medications
Description: standard medications was giving to subjects according guidelines
Study NCT04905277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol 50 MG
Description: 50 mg Atenolol daily
Study NCT06664905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 10 Repetition Maximum (RM)
Study NCT06664905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: No exercise
Study NCT06667063 — intervention group
Intervention type: OTHER
Intervention: Nasal swab/Nasopharyngeal swab/Blood sample collection
Description: Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
Study NCT06667063 — intervention group
Intervention type: OTHER
Intervention: Nasal swab/Nasopharyngeal swab/Blood draw
Description: Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
Study NCT05845021 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surgeon-Initiated Bone Health Referral Pathway
Description: Described in arm description
Study NCT04905277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo daily
Study NCT06054230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genomic Sequencer
Description: Genomic Sequencing Device
Study NCT04513613 — intervention group
Intervention type: DEVICE
Intervention: Procedure/Surgery: Robotic-PVI
Description: Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
Study NCT06676475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: 2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).
Study NCT06676475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX-A
Description: 2ml of BTX
Study NCT06676475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: 2 ml of saline
Study NCT06614543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal Replacement
Description: These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.
Study NCT05283902 — intervention group
Intervention type: BIOLOGICAL
Intervention: ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
Description: In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
Study NCT06620731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c capsule
Description: Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.